<DOC>
	<DOCNO>NCT00207311</DOCNO>
	<brief_summary>This prospective , multi-center , randomize , placebo-controlled trial subject histological evidence &gt; 33 % hepatic steatosis nonalcoholic steatohepatitis ( NASH ) chronic hepatitis C. Patients previously treat hepatitis C ( treatment naive ) enrol .</brief_summary>
	<brief_title>Study Treatment Significant Steatosis With Xenical Followed Treatment Hepatitis C With Pegasys/Copegus</brief_title>
	<detailed_description>Recent evidence suggest patient concomitant chronic HCV infection NASH significant hepatic steatosis ( &gt; 33 % ) respond le well standard antiviral therapy . As previously note , 10 % patient chronic HCV infection concomitant NASH even great percentage associate hepatic steatosis . No prospective study date evaluate sustained viral response rate standard antiviral therapy group patient previously treat medication eliminate improve underlie NASH and/or hepatic steatosis . Primary Outcome : To determine decrease amount NASH hepatic steatosis overweight ( BMI &gt; 27 kg/m2 ) HCV patient result improve overall SVR PEGASYS Copegus . Secondary Outcome : 1.To determine amount steatosis , necroinflammatory activity , fibrosis change group participant chronic hepatitis C NASH significant steatosis treat Xenical vs. placebo 36 week . 2 . To assess difference insulin resistance , measure QUICKI score , treatment Xenical Xenical placebo diet exercise .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Orlistat</mesh_term>
	<criteria>Participants must willing give write informed consent able adhere dose visit schedule . HCVAb HCVRNA PCR Positive least 6 month Serum positive HCVRNA PCR assay Treatment naïve participant hepatitis C genotype 1 , 2 , 3 , 4 Body mass index &gt; 27 Liver biopsy within 12 month pathology report confirm histological diagnosis consistent CHCand NASH hepatic steatosis &gt; 33 % Compensated liver disease minimum hematological , biochemical , serologic criterion Enrollment Visit ( WNL = within normal limit ) : Hemoglobin value &lt; 12 gm/dL female &lt; 13 gm/dL male WBC &lt; 3,000/ mm3 Neutrophil count &lt; 1,500/mm3 Platelets &lt; 65,000/ mm3 Direct bilirubin within 20 % ULN Indirect bilirubin WNL Albumin &gt; 3 gm/dL creatinine &lt; 20 % ULN TSH WNL Alpha fetoprotein value &lt; 100 ng/mL Reconfirmation documentation sexually active female subject childbearing potential practicing adequate contraception method , monogamous relationship male partner vasectomy use condom + spermicide ) treatment period six month follow last dose study medication Reconfirmation sexually active male subject practice two acceptable method contraception Women pregnant breastfeeding Males whose female partner pregnant No Thiazolidinedione liver biopsy and/or entire study Hepatitis C nongenotype 1,2,3 4 Previous antiviral therapy treatment Hepatitis C Suspected hypersensitivity interferon , PEGinterferon , ribavirin , Xenical Any cause liver disease chronic hepatitis C NASH steatosis , include limited : Hemochromatosis Alpha1 antitrypsin deficiency Coinfection HBV Wilson 's disease Autoimmune hepatitis Alcoholic liver disease Drugrelated liver disease Any condition would prevent subject liver biopsy Hemoglobinopathies ( e.g. , Beta Thalassemia ) Evidence advance liver disease Patients organ transplant cornea hair transplant Any known preexist medical condition could interfere subject 's participation completion protocol : Preexisting psychiatric condition , especially severe depression , history severe psychiatric disorder , major psychosis , suicidal ideation and/or suicidal attempt exclude CNS trauma preexisting/active seizure disorder uncontrolled medication Significant cardiovascular dysfunction within past 12 month Poorly control diabetes mellitus Chronic pulmonary disease document pulmonary hypertension Immunologically mediate disease ( Crohn 's disease , ulcerative colitis ) , rheumatoid arthritis , idiopathic thrombocytopenia purpura , systemic lupus erythematosus , autoimmune hemolytic anemia , scleroderma , severe psoriasis , clinical cryoglobulinemia vasculitis Any medical condition requiring , likely require chronic systemic administration steroid Evidence active suspect cancer history malignancy risk reoccurrence ≥ 20 % within 2 year Active clinical gout Substance abuse Participants willing counseled/abstain alcohol Participants clinically severe retinal abnormality Any condition opinion investigator would make patient unsuitable enrollment , could interfere patient participate complete protocol Known positive HIV Inability/unwillingness provide inform consent abide requirement study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Fatty Liver</keyword>
	<keyword>NASH</keyword>
	<keyword>Steatohepatitis</keyword>
</DOC>